UBS Group
BMY.RT

UBS Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

UBS Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-627,973
Closed -$433K – 9947
2020
Q4 		$433K Sell
627,973
-60,621
-9% -$129K ﹤0.01% 4707
2020
Q3 		$1.55M Sell
688,594
-229,288
-25% -$655K ﹤0.01% 3297
2020
Q2 		$3.29M Sell
917,882
-4,517,312
-83% -$16.3M ﹤0.01% 2411
2020
Q1 		$20.7M Buy
5,435,194
+132,446
+2% +$436K 0.01% 967
2019
Q4 		$16M Buy
+5,302,748
New +$13.8M 0.01% 1538

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

UBS Group's BMY.RT Position: Q1 2021 in Review

UBS Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 627,973 shares — an estimated $433K sold.

UBS Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $20.7M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • UBS Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • UBS Group sold 627,973 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $433K.
  • UBS Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • UBS Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $20.7M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.